Breaking down the dorzolamide shortage; impact on patients: Shortages reveal how generic molecules are supplied in ophthalmology industry.

The article explores the impact on patients of the shortage of the first-line glaucoma therapy, dorzolamide in the U.S. Topics covered include the revelations of the shortages on how generic molecules are supplied in the ophthalmology industry, the damage brought by the lack of accountability and commitment from generic manufacturers of dorzolamide, and brinzolamide as the most logical alternative to dorzolamide.